Metastatic Hormone Refractory Prostate Cancer Active Not Recruiting Phase 2 Trials for Abiraterone (DB05812)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02703623Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerTreatment
NCT02036060Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.Treatment